Clinical Lymphoma, Myeloma and Leukemia

Published by: Elsevier Inc.  

People

  1. Usmani
    Usmani
  2. Giralt
    Giralt
  3. Lesokhin
    Lesokhin
  4. Landau
    Landau
  5. Hassoun
    Hassoun
  6. Hultcrantz
    Hultcrantz
  7. Korde
    Korde
  8. Mailankody
    Mailankody
  9. Mauro
    Mauro
  10. Shah
    Shah

Groups

  1. Hematologic Malignancies, Division of (330)
  2. Department of Medicine (327)
  3. Center for Hematologic Malignancies (304)
  4. Adult Leukemia (117)
  5. Myeloma (96)
  6. Survivorship Research (85)
  7. Hematologic Malignancies Research (84)
  8. Bone Marrow Transplant (77)
  9. Sloan Kettering Institute Postdocs (68)
  10. Hematology-Oncology Fellows (63)
Search Within
Formats
  1. Meeting Abstract (311)
  2. Journal Article (76)
  3. Review (10)
  4. Editorial (2)
  5. Conference Paper (1)
  6. Guidelines (1)
  7. Research Letter (1)
Groups
  1. Hematologic Malignancies, Division of (330)
  2. Department of Medicine (327)
  3. Center for Hematologic Malignancies (304)
  4. Adult Leukemia (117)
  5. Myeloma (96)
  6. Survivorship Research (85)

More Groups

People
  1. Saad Usmani (81)
  2. Sergio Giralt (60)
  3. Alexander Lesokhin (57)
  4. Heather Landau (53)
  5. Hani Hassoun (51)
  6. Malin Hultcrantz (50)

More People

Years
  1. 2025 (9)
  2. 2024 (44)
  3. 2023 (79)
  4. 2022 (64)
  5. 2021 (40)
  6. 2020 (29)

More Years

Publishers
  1. Elsevier Inc. (402)

Results (402)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of ABBV-383, a BCMA bispecific antibody, in black patients with relapsed/refractory multiple myeloma: A subgroup analysis of a phase 1 trial
    Meeting Abstract

    D'Souza, A.; Rodriguez-Valdes, C.; Kumar, S.; Chung, A.; Tuchman, S.; Safah, H.; Weisel, K.; Teipel, R.; Korde, N.; Vij, R.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Genomic landscape of IgM MGUS and stable versus progressive asymptomatic Waldenström macroglobulinemia patients
    Meeting Abstract

    Bagratuni, T.; Theologi, O.; Vlachos, C.; Aktypi, F.; Maclachlan, K.; Kollias, I.; Mavrianou-Koutsoukou, N.; Liacos, C.; Papadimou, A.; Taouxi, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Interim results of a phase 2 trial of isatuximab-lenalidomide for patients with High-Risk Smoldering Multiple Myeloma
    Meeting Abstract

    Thomas, S.; Manasanch, E.; Korde, N.; Lee, H.; Jagannath, S.; Becnel, M.; Kaufman, G.; Patel, K.; Iyer, S.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Sonrotoclax plus dexamethasone was tolerable and demonstrated antimyeloma activity in patients with relapsed/refractory multiple myeloma harboring t(11;14)
    Meeting Abstract

    Costa, A.; Dhakal, B.; Hultcrantz, M.; Bal, S.; Chuah, H.; Kaufman, J. L.; Kazandjian, D.; Nathwani, N.; Royle, G.; Sborov, D. W.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Absolute lymphocyte count at Day 30 (not earlier) and early CRS predict delayed responses to teclistamab: Results from the US Myeloma Immunotherapy Consortium
    Meeting Abstract

    Banerjee, R.; Kaur, G.; Razzo, B.; Portuguese, A.; Sidana, S.; Richards, T.; Grajales-Cruz, A.; Richard, S.; Shune, L.; Khouri, J.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Maintenance therapy cessation for multiple myeloma patients with three-year sustained mrd negative remissions
    Meeting Abstract

    Korde, N.; Hassoun, H.; Landau, H.; Hamid, S.; Derkach, A.; Hultcrantz, M.; Mailankody, S.; Tan, C.; Shah, U.; Maclachlan, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Single cell whole genome measurement of genomic heterogeneity and clonal evolution in multiple myeloma
    Meeting Abstract

    McPherson, A.; Maclachlan, K.; Myers, M.; Satas, G.; Garcés, J. J.; Lee, H.; Bahlis, N. J.; Usmani, S.; Shah, S.; Maura, F.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Mezigdomide (MEZI), tazemetostat (TAZ), and dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Preliminary results from the CA057-003 trial
    Meeting Abstract

    Costa, L.; Popat, R.; Siegel, D.; Schjesvold, F.; Usmani, S.; Bahlis, N. J.; Oriol, A.; Chu, M.; Ali, S. A.; Ramasamy, K.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Para-medullary (PMD) and extra-medullary (EMD) myeloma demonstrate increased copy number aberration, mutational burden, structural variants and genomic complexity compared to marrow-based myeloma
    Meeting Abstract

    Maclachlan, K.; Garcés, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C.; Mailankody, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • SOHO state of the art updates and next questions: Will CAR-T replace ASCT in NDMM
    Review

    Jurgens, E.; Usmani, S. Z.
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save

    • Clinical Lymphoma, Myeloma and Leukemia – authorized name for:

    Name ISSN / ISBN Publisher
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Cancer Media Group
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma Myeloma & Leukemia 2152-2650 Cig Media Group, Lp
    Clinical Lymphoma, Myeloma & Leukemia 21522669 Unknown
    Clinical Lymphoma, Myeloma & Leukemia 2152-2650 Unknown
    Clinical Lymphoma, Myeloma & Leukemia 1368-8375 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522669 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Unknown
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 152-2650 2021
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Ltd
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2022
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2023
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2025
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2024
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522669 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 The Author(s)
    Clinical Lymphoma, Myeloma and Leukemia 21522650 The Authors
    Clinical Lymphoma, Myeloma and Leukemia 21522650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 21522650 2021
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Clinical Lymphoma, Myeloma and Leukemia 2152-2650 Elsevier Inc.
    Unknown (2152-2650) 2152-2650 Unknown